

Paola Piccini

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9174308/paola-piccini-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

4,959

citations

33

h-index

70

g-index

73

ext. papers

5,646

ext. citations

7.5

avg, IF

5.07

L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 66 | Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. <i>Nature Neuroscience</i> , 1999 , 2, 1137-40 | 25.5 | 582 |
| 65 | Compulsive drug use linked to sensitized ventral striatal dopamine transmission. <i>Annals of Neurology</i> , 2006 , 59, 852-8 | 9.4 | 359 |
| 64 | Microglial activation in presymptomatic Huntington's disease gene carriers. <i>Brain</i> , 2007 , 130, 1759-66 | 11.2 | 324 |
| 63 | The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. <i>Annals of Neurology</i> , 1999 , 45, 577-82 | 9.4 | 275 |
| 62 | Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. <i>Brain</i> , 2011 , 134, 969-78 | 11.2 | 245 |
| 61 | Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. <i>Annals of Neurology</i> , 2000 , 48, 689-695 | 9.4 | 211 |
| 60 | Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. <i>JAMA Neurology</i> , 2014 , 71, 83-7 | 17.2 | 205 |
| 59 | Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. <i>Brain</i> , 2005 , 128, 2977-86 | 11.2 | 205 |
| 58 | Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. <i>Neurobiology of Disease</i> , 2010 , 40, 216-21 | 7.5 | 179 |
| 57 | Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. <i>Scientific Reports</i> , 2017 , 7, 1398 | 4.9 | 178 |
| 56 | Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1340-9 | 15.9 | 172 |
| 55 | Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. <i>Human Brain Mapping</i> , 2011 , 32, 258-70 | 5.9 | 147 |
| 54 | Hypothalamic involvement in Huntington's disease: an in vivo PET study. <i>Brain</i> , 2008 , 131, 2860-9 | 11.2 | 137 |
| 53 | Endogenous dopamine release after pharmacological challenges in Parkinson's disease. <i>Annals of Neurology</i> , 2003 , 53, 647-53 | 9.4 | 136 |
| 52 | Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. <i>Movement Disorders</i> , 2011 , 26, 1997-2003 | 7 | 126 |
| 51 | Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. <i>Neurology</i> , 2012 , 79, 523-30 | 6.5 | 125 |
| 50 | Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. <i>Neurobiology of Disease</i> , 2015 , 83, 115-21 | 7.5 | 87 |

| | | | |
|----|--|------|----|
| 49 | Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson's disease. <i>Brain</i> , 2016 , 139, 2224-34 | 11.2 | 84 |
| 48 | Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. <i>Brain</i> , 2015 , 138, 3003-15 | 11.2 | 74 |
| 47 | Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis. <i>Biological Psychiatry</i> , 2016 , 80, 62-72 | 7.9 | 73 |
| 46 | Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. <i>Brain</i> , 2015 , 138, 3016-29 | 11.2 | 71 |
| 45 | 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997 , 17, 943-9 | 7.3 | 68 |
| 44 | In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1112-8 | 8.9 | 67 |
| 43 | Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. <i>Brain</i> , 2015 , 138, 110-9 | 11.2 | 60 |
| 42 | Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias. <i>Neurology</i> , 2016 , 86, 1152-8 | 6.5 | 60 |
| 41 | Acute and chronic effects of clozapine in essential tremor. <i>Movement Disorders</i> , 1999 , 14, 468-72 | 7 | 60 |
| 40 | Functional brain imaging in the differential diagnosis of Parkinson's disease. <i>Lancet Neurology</i> , 2004 , 3, 284-90 | 24.1 | 57 |
| 39 | Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. <i>Movement Disorders</i> , 2017 , 32, 181-192 | 7 | 56 |
| 38 | Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. <i>Neurobiology of Disease</i> , 2014 , 65, 203-10 | 7.5 | 54 |
| 37 | The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. <i>Neurobiology of Aging</i> , 2015 , 36, 1736-1742 | 5.6 | 39 |
| 36 | LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: A LONGITUDINAL PET STUDY. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, e1.17-e1 | 5.5 | 39 |
| 35 | Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. <i>Movement Disorders</i> , 2016 , 31, 1020-6 | 7 | 38 |
| 34 | Single versus multiple impulse control disorders in Parkinson's disease: an [(11)C]-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. <i>Journal of Neurology</i> , 2015 , 262, 1504-14 | 5.5 | 35 |
| 33 | New developments of brain imaging for Parkinson's disease and related disorders. <i>Movement Disorders</i> , 2006 , 21, 2035-41 | 7 | 31 |
| 32 | C-PE2I and F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. <i>Movement Disorders</i> , 2018 , 33, 117-127 | 7 | 30 |

| | | | |
|----|---|------|----|
| 31 | Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. <i>Journal of Neurology</i> , 2015 , 262, 2653-61 | 5.5 | 30 |
| 30 | Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system. <i>Brain</i> , 2019 , 142, 2023-2036 | 11.2 | 25 |
| 29 | Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review. <i>Neurological Sciences</i> , 2017 , 38, 2095-2101 | 3.5 | 25 |
| 28 | Chronic exposure to dopamine agonists affects the integrity of striatal D receptors in Parkinson's patients. <i>NeuroImage: Clinical</i> , 2017 , 16, 455-460 | 5.3 | 24 |
| 27 | Neurodegenerative movement disorders: the contribution of functional imaging. <i>Current Opinion in Neurology</i> , 2004 , 17, 459-66 | 7.1 | 17 |
| 26 | Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 301-309 | 5.2 | 14 |
| 25 | Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. <i>Movement Disorders</i> , 2017 , 32, 235-240 | 7 | 14 |
| 24 | Pallidal dopaminergic denervation and rest tremor in early Parkinson's disease: PPMI cohort analysis. <i>Parkinsonism and Related Disorders</i> , 2018 , 51, 101-104 | 3.6 | 13 |
| 23 | Problematic Internet use in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 482-7 | 3.6 | 12 |
| 22 | Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1505-1515 | 7 | 10 |
| 21 | PET Imaging in Huntington's Disease. <i>Journal of Huntingtons Disease</i> , 2015 , 4, 287-96 | 1.9 | 9 |
| 20 | Towards molecular imaging of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 262-72 | 5 | 9 |
| 19 | Dyskinesias after transplantation in Parkinson's disease. <i>Lancet Neurology</i> , 2002 , 1, 472 | 24.1 | 9 |
| 18 | Outcome of cell suspension allografts in a patient with Huntington's disease. <i>Annals of Neurology</i> , 2018 , 84, 950-956 | 9.4 | 9 |
| 17 | Molecular Imaging of Neuroinflammation in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018 , 141, 347-363 | 4.4 | 9 |
| 16 | Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1336-41 | 3.6 | 8 |
| 15 | Brain Imaging and Impulse Control Disorders in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2019 , 19, 67 | 6.6 | 4 |
| 14 | Clinical utility of DaTscan[(123I)-Ioflupane Injection] in the diagnosis of Parkinsonian Syndromes. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2013 , 3, 33-39 | 5.4 | 4 |

| | | | |
|----|---|-----|---|
| 13 | Astrocytes in Parkinson's disease: from preclinical assays to in vivo imaging and therapeutic probes. <i>Neurobiology of Aging</i> , 2020 , 95, 264-270 | 5.6 | 4 |
| 12 | Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020 , 28, 102409 | 5.3 | 3 |
| 11 | Multimodal dopamine transporter (DAT) imaging and magnetic resonance imaging (MRI) to characterise early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020 , 79, 26-33 | 3.6 | 3 |
| 10 | SUSCEPTIBILITY WEIGHTED IMAGING TO DETECT NIGRAL IRON ACCUMULATION IN PARKINSON'S DISEASE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, e4.91-e4 | 5.5 | 2 |
| 9 | Dissociable effects of age and Parkinson's disease on instruction-based learning. <i>Brain Communications</i> , 2021 , 3, fcb175 | 4.5 | 2 |
| 8 | Restorative Strategies in Movement Disorders: the Contribution of Imaging. <i>Current Neurology and Neuroscience Reports</i> , 2017 , 17, 98 | 6.6 | 1 |
| 7 | Impulse Control Disorders in Parkinson's Disease: A Review. <i>Current Psychiatry Reviews</i> , 2012 , 8, 235-246 | 0.9 | 1 |
| 6 | Dopamine Transporter Density in Parkinson's Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias 2019 , 3, 10000 | | 1 |
| 5 | Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2021 , 87, 61-69 | 3.6 | 1 |
| 4 | Parkinson's disease laterality: a C-PE2I PET imaging study. <i>Journal of Neurology</i> , 2021 , 268, 582-589 | 5.5 | 0 |
| 3 | PO105 Levodopa-induced dyskinesias in parkinson's: imaging of striatal dat density over time. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A39.2-A39 | 5.5 | |
| 2 | PO088 Nigral iron susceptibility in parkinson's disease: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A34.4-A35 | 5.5 | |
| 1 | PET Imaging in Multiple Sclerosis: Focus on the Translocator Protein 2014 , 757-773 | | |